Noticias y eventos de GeoVax Labs Inc (GOVX)

$0.140

-0.016 (-11.27%)Al cierre

Noticias de GOVX

8.505-26stocktwits

GeoVax Shifts Focus to Vaccine and Cancer Therapies Amid Stock Resale

2.005-26NASDAQ.COM

Biotech Stocks Surge with Akari Leading the Rally

2.005-22NASDAQ.COM

Multiple Companies Experience Significant Stock Price Gains

8.505-19stocktwits

GeoVax Vaccine Development Gains Regulatory Support

4.502-13Benzinga

U.S. Stocks Decline in Morning Trade as Inflation Rate Eases

9.501-09Benzinga

Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%

4.512-19Benzinga

Dow Rises by More Than 200 Points; Conagra Stock Declines Following Q2 Earnings Report

8.510-17SeekingAlpha

GeoVax Labs Seeks Approval to Offer 11.9 Million Shares of Common Stock for Shareholders

1.009-23Globenewswire

Live Stream Registration Now Open for Day 2 of the Emerging Growth Conference 86 on September 25

1.008-18Globenewswire

Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open

Ver más noticias

Eventos de GOVX

11/6 19:00

GeoVax Labs Terminates CEO David A. Dodd

In a regulatory filing, the company stated, "On November 5, 2026, David A. Dodd was terminated as President and Chief Executive Officer of the GeoVax Labs, effective immediately. Mr. Dodd remains a director of the company and the Chairman of the Board of Directors. On November 5, 2026, the Board of Directors determined to terminate Mr. Dodd's employment, effective immediately, and to treat the termination as a termination for "Cause" as defined in the Employment Agreement between the company and Mr. Dodd, dated September 1, 2018. The Board of Directors based this determination on Mr. Dodd's refusal to comply with Board-approved directives."

11/4 06:30

E.F. Hutton Acts as Sole Underwriter

E.F. Hutton & Co. is acting as sole book-running manager and sole underwriter in connection with this offering.

9/17 16:30

Selling Stockholders Plan to Sell Up to 11.4M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 11.4M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

6/26 14:00

CDC Raises Response Level to Ebola Outbreak in Congo

The Centers for Disease Control raised its response to the Ebola outbreak in the Democratic Republic of Congo to its highest level on Friday , but said the risk of Ebola's spread in the U.S. remained low, reported Reuters. Companies working on Ebola testing and defense solutions include NanoViricides (NNVC), GeoVax Labs (GOVX) and Co-Diagnostics (CODX).

6/12 13:30

HHS Supports Development of Bundibugyo Ebola Vaccine

The HHS ASPR account on X stated: "BARDA is supporting development of Bundibugyo ebolavirus vaccine candidates through the Rapid Response Partnership Vehicle Consortium. We're interested in candidates that leverage the vesicular stomatitis virus platform, which has proven to require just one dose to provide protection for other filoviruses." Vaccine developers include GeoVax Labs (GOVX), Soligenix (SNGX) and Moderna (MRNA).

Ver más eventos

Noticias de GOVX

Eventos de GOVX

Artículos relacionados